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Abstract
Purpose A number of observational clinical studies suggest that prior primary tumor treatment favorably influences the 
course of metastatic prostate cancer (PCa), but its mechanisms of action are still speculative. Here, we describe the long-
lasting sensitivity to various forms of androgen deprivation in patients after radical prostatectomy (RP) for locally advanced 
PCa as one potential mechanism.
Methods A consecutive series of 115 radical prostatectomies after inductive therapy for T4 prostate cancer was re-analyzed, 
and long-term survival, as well as recurrence patterns and responses to different forms of hormonal manipulation, were 
assessed.
Results The estimated biochemical response-free, PCa-specific, and overall survival rates after 200 months were 20%, 65%, 
and 47% with a median overall survival of 156 months. The majority of patients, although not cured of locally advanced PCa 
(84/115), showed long-term survival after RP. PCa-specific and overall survival rates of these 84 patients with biochemical 
recurrence were 61% and 44% at 150 months. Long-term sensitivity to ADT was found to be the main reason for the favorable 
tumor-specific survival in spite of biochemical recurrence.
Conclusions Sensitivity to primary or secondary hormonal manipulation was the main reason for the long-term survival of 
patients who had not been cured by surgery only. The results suggest that treatment of the primary tumor-bearing prostate 
delays castration-resistant PCa and enhances the effect of hormonal therapies in a previously unknown manner. The under-
lying cellular and molecular mechanisms need to be explored in more detailed analyses, which could profoundly impact 
treatment concepts of locally advanced and metastatic PCa.
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Introduction
Patients with locally inoperable (T4) or primary metastatic 
prostate cancer (PCa) are commonly regarded as incurable. 
Current guidelines recommend systemic therapy such as 
androgen deprivation treatment (ADT) or chemotherapy 
combined with external beam radiotherapy to prolong sur-
vival without curation [1–3]. Emerging data suggest an addi-
tional benefit of local primary tumor treatment in the natural 
course of recurrent or metastatic disease [4–7]. However, no 
hypothesis has fundamentally been corroborated regarding 
how the treatment of the primary tumor could influence the 
course of systemic PCa.
We recently published a series of patients with cT4 PCa, 
defined as a fixed mass by digital rectal examination (DRE) 
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in combination with high or very high prostate-specific anti-
gen (PSA) levels (median 37.6 ng/ml; range 2.44–284 ng/
ml) in many cases (n = 39 patients with PSA ≥ 50 ng/ml)
[8]. These patients underwent inductive hormonal treatment 
until the PSA nadir, which was predictively achieved after 
6–7 months. We subsequently observed a reliable clinical 
remission at the time of the PSA nadir, which allowed a 
safe removal of the prostate in almost every patient (10.3% 
Clavien 3, no Clavien 4/5 complications). Depending on 
clinical responses and the decision of the surgeon, some 
patients were operated on before the PSA nadir had been 
achieved. The vast majority of patients did not reach a non-
detectable PSA after surgery, suggesting a curative effect 
of this approach for a minority of less than 20%. After a 
median follow-up of 75 (9–167) months, however, we found 
an unexpectedly low tumor-specific death rate of 18% [8].
To define the underlying mechanisms of this favorable 
outcome, we updated the clinical course of these T4 patients 
after radical prostatectomy (RP) in more detail, focusing on 
long-term survivors after proven biochemical recurrence.
Materials and methods
Survival and treatment data of patients with initial T4 PCa, 
who underwent RP after inductive ADT, were updated. The 
operations were performed between 2000 and 2014. All 
patients were initially found inoperable due to a fixed tumor 
mass at DRE, leading to clinical stage T4. While only a few 
patients had an MRI or CT scan at the time of their diagno-
sis, the clinical impression was corroborated by transrectal 
ultrasound (TRUS) demonstrating advanced, non-organ-
confined disease, highly elevated baseline PSA levels and/or 
large foci in a biopsy confirming an undifferentiated tumor. 
Baseline demographic data are summarized in Table 1.
In general, inductive ADT consisted of LHRH agonists 
with or without antiandrogens, which was maintained until 
PSA nadir was reached. In addition to RP, regular lymphad-
enectomy was performed for the right and left external iliac 
region (including the obturator fossa). After the introduction 
of the daVinci robotic system (Intuitive Surgical Inc., Sun-
nyvale, CA, USA) at our center in 2006, all patients were 
treated with robot-assisted radical prostatectomy (RARP). 
Histopathologic findings of surgical specimens are summa-
rized in Table 1.
Statistics
Survival outcomes were analyzed with the Kaplan–Meier 
method and log-rank test. Statistical analysis was performed 
using SPSS version 23.0 (SPSS Inc., IBM Corp., Armonk, 
NY, USA).
Results
After a median follow-up of 81 months (inter-quartile 
range (IQR): 50–134), a total of 44 patients had died 
(38.3%) with a median time to death of 67 months (Fig. 1: 
OS all patients), 19 of which (43.1%) died from causes 
unrelated to PCa after a median time of 75 months. The 
estimated biochemical response-free, PCa-specific, and 
overall survival rates after 200 months were 20%, 65%, 
and 47%, respectively (Fig. 1), with a median overall sur-
vival of 156 months. Of all 115 patients, 21 patients had 
a complete biochemical response and never received any 
adjuvant therapies (Fig. 2: flow chart). Overall and PCa-
specific survival rates of these 21 patients were 81% and 
100% after 107 months, respectively. Postsurgical tumor 
characteristics of this subgroup of patients are summarized 
in Suppl. Table 2. Of the remaining patients, 84 had a bio-
chemical recurrence and received further treatment. The 
estimated tumor-specific and overall survival rates of these 
84 patients at 150 months were 61% and 44%, respectively 
(Suppl. Fig. 1a and b).
In total, there were 46 patients (40%) with positive sur-
gical margin after prostatectomy, half of them underwent 
additional radiation therapy of the prostatic fossa during 
their further disease course.
Long-term data of patients with prolonged survival in 
spite of biochemical recurrence revealed long-term sen-
sitivity to primary or secondary hormonal manipulation 
as the most important prognostic variable. In total, 47 of 
84 patients with biochemical recurrence were still alive 
after 95 months of follow-up. Thirty-one of them received 
Table 1  Patients` demographics and pathological data
SM surgical margins, LNI lymph node invasion
Variables Total n = 115
Age, yr, median (range) 66 (50–76)





Inductive ADT duration months, median (range) 6 (2–20)





Positive SM 46 (40%)
LNI 38 (33%)
Positive SM and LNI 26 (22.6%) 
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ADT with a mean biochemical response for 49 months. 
Only 13 patients developed castration-resistant PCa after 
44 months of sensitivity to ADT alone.
We selected two informative cases to illustrate the phe-
nomenon of ongoing hormone sensitivity (HS) for many 
years (Suppl. Table 1). One of these two patients had stopped 
adjuvant ADT five years after surgery because of a non-
detectable PSA, temporarily had extremely disseminated 
bone metastases, and presented in moribund condition with 
a PSA of 8144 ng/ml. His metastases completely disappeared 
after the re-initiation of ADT. The total treatment time with 
ADT has now been more than 9 years, and PSA has returned 
to < 0.03 ng/ml (undetectable) 5 years after the re-start of treat-
ment and 15 years after the initial diagnosis. Other patients, 
such as the second patient, developed a slowly increas-
ing ADT-resistant PSA progression before their PSA again 
responded to tertiary hormonal treatment with abiraterone. 
These secondary complete responses persisted for more than 
3 years and are ongoing.
Fig. 1  a Survival curve for biochemical recurrence-free survival of patients after radical prostatectomy (RP) (n = 72). b Survival curve for over-
all and primary metastatic prostate cancer (PCa)-specific survival of all patients after RP
Fig. 2  Flowchart of the total patient cohort with long-term follow-up
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Discussion
The androgen sensitivity of metastatic PCa was first 
described by C. B. Huggins in 1941 [9]; this finding was 
awarded with a Nobel prize in 1966. Since then, ADT, 
starting as surgical castration, has remained the standard 
of care for metastatic and/or locally advanced PCa. Surgi-
cal castration has largely been replaced by LHRH agonist 
or antagonist treatment, which is regarded as being as 
effective as castration [10]. Unfortunately, the secondary 
resistance of metastatic PCa to ADT seems unavoidable. 
In 2002, Eisenberger and Carducci summarized that “The 
development of a hormone-independent state is a categori-
cal and irreversible phenomenon observed in the majority 
of patients and occurs within an almost predictable time 
frame after the initiation of androgen deprivation” [11]. 
At that time, all available studies uniformly found median 
times to progression and tumor-related death from 12 to 
18 months and 2–3 years, respectively. Survival times 
had not been significantly improved by the first-genera-
tion androgen receptor antagonists, such as flutamide or 
bicalutamide, often summarized as secondary hormonal 
treatment [12, 13].
During the past 15 years, however, survival times for 
metastatic PCa have remarkably increased. This may 
partly be caused by the earlier detection of metastases. 
This result is certainly influenced by the addition of new 
treatment concepts, all with a proven survival benefit of 
several months [14–17]. To the best of our knowledge, 
long-lasting or even unlimited responses to any of these 
treatment modalities have never been described or system-
atically analyzed. The Cou-AA-302 trial, which compared 
abiraterone plus prednisone with placebo plus prednisone 
in castration-resistant PCa, demonstrated a radiographic 
progression-free survival rate of ~ 15% after 33 months. 
A survival plateau of 15% or less, indicating long-term 
responses beyond 33 months, has not yet been published 
[18]. One must assume that most of the 15% of patients 
without radiographic progression already had rising PSA 
values at their last control.
Attempts to overcome castration resistance are almost 
as old as ADT itself. Huggins hypothesized that androgens 
produced by the adrenal glands induce castration resist-
ance and he—frustraneously—tested bilateral adrenalec-
tomy as a salvage treatment for castration-resistant PCa 
[19]. Meanwhile, the molecular basis of hormone resist-
ance could at least partly be clarified on the level of the 
androgen receptor: modifications of the receptor allow for 
promiscuitive stimulation by hormones such as ACTH, 
TSH or even by anti-androgens such as flutamide [20, 21]. 
Splice variants of the receptor, such as ARV-7 [22], lack 
the androgen-binding domain, thus leading to permanent 
tumor stimulation even in the absence of any hormonal 
stimulus. Such splice variants are described as one main 
reason for cross-resistance between abiraterone and enza-
lutamide [22–24].
Our cases after radical prostatectomy with still elevated 
PSA levels (Suppl. Fig. 1) differ from all published experi-
ences with the hormone manipulation of metastatic PCa: 
they have ongoing responses to various forms of hormo-
nal treatment over time intervals that exceed all previously 
described time frames.
Similar phenomena have been previously observed in 
other settings and could be based on the same biological 
mechanisms. A relatively benign course for patients with 
PSA recurrence after RP (15 year PCa-specific 50%; Glea-
son ≥ 8) [25] could be caused by the long-lasting effects of 
delayed ADT, in a very similar manner to our results after 
inductive therapy [8]. Patients with recurrent mPC after 
prior local therapy have longer survival than comparable 
patients with de novo mPC [26], and this effect has been 
translated into modern combination therapies such as ADT 
plus apalutamide in the Titan study [27]. For nonmetastatic 
castration-resistant PCa patients, an impressively long sen-
sitivity to apalutamide and darolutamide has been observed. 
Again, three-quarters of these patients had prior local ther-
apy. Finally, patients primarily presenting with limited bone 
metastases seem to benefit from the addition of the treatment 
of their primary tumor to the standard of care [28].
Our data suggest that long-lasting hormone-dependent 
complete remissions of metastatic PCa occur more fre-
quently than anticipated, predominantly in patients after 
local treatment. The sources that define castration resist-
ance as an event that unavoidably occurs after 18–30 months 
uniformly date back to the 1990s. At that time, only a minor-
ity of patients with advanced or metastatic PCa had a prior 
prostatectomy or other forms of local treatment, such as 
radiotherapy.
Messing et  al. were the first to present data in 1999 
that demonstrated an impressive tumor-specific survival 
benefit after prostatectomy followed by immediate ADT 
compared to prostatectomy alone for patients affected by 
tumor-involved lymph nodes (pN + ; for decades, regarded 
as incurable) [29]. Of 47 patients randomized for combined 
treatment, only 17 had died, seven of which died because of 
PCa. Among 51 patients randomized for prostatectomy only, 
28 deaths were encountered, of which 25 were PCa-related. 
Overall, PCa-specific and progression-free survival were 
significantly improved for patients randomized for prosta-
tectomy plus ADT. Bhindi et al. retrospectively compared 
158 carefully matched pN + patients treated with prostatec-
tomy plus castration versus castration alone and found an 
equally impressive difference in favor of the combination 
therapy. The risk of dying from PCa was reduced by more 
than 50%, which translated into a significant improvement 
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in 20 years of OS [30]. It, therefore, seems that the combi-
nation of prostatectomy plus ADT in this particular micro-
metastatic situation potentiates the effects achieved by each 
of the two treatment modalities alone, again corroborating 
the hypothesis of a modulating effect of prostate removal on 
the hormone sensitivity of metastatic cells. Such sensitivity 
was also seen in patients who underwent salvage extended 
pelvic lymph node dissection subsequent to PSA recurrence 
after radical prostatectomy [31].
Another unsolved paradox that could also be explained 
by the hypothesis of an ADT-modulating effect of prosta-
tectomy is the contradictory results of radiotherapy stud-
ies that aim to treat or to prevent biochemical recurrences 
after prostatectomy: Irradiation significantly prevented PSA 
recurrences, which, however, did not translate into a survival 
benefit [32]. Prolonged sensitivity to ADT would equally 
be present both in irradiated and non-irradiated patients 
and could therefore counterbalance any former benefit of 
radiotherapy.
In principle, large amounts of data have been published 
that suggest a positive influence of a prior prostatectomy or 
other forms of local treatment on the prognosis of patients 
with metastatic PCa [4, 5, 33]. However, to the best of our 
knowledge, a hypothesis referring to a clear mode of action 
is still missing. The available data, in spite of scarce evi-
dence, have fueled a discussion about the role of prosta-
tectomy in patients with synchronous distant metastases. In 
analogy to kidney cancer, these operations are character-
ized as “cytoreductive”, for which a recent comparative case 
series was unable to demonstrate a survival benefit [34]. The 
STAMPEDE trial on the radiotherapy of the prostate in men 
with metastatic PCa could not find an overall survival advan-
tage by local treatment for the complete study population 
but found an advantage for a subgroup defined by low meta-
static burden according to the CHAARTED definition [7]. 
Our experience suggests that at least a minority of patients 
presenting with synchronous bone metastases should benefit 
from the removal of the primary tumor via the prevention 
of ADT-refractory disease. Such operations should rather be 
characterized as “hormone-sensitizing” instead of “cytore-
ductive”. However, the patient selection, role and extent of 
pretreatment and quantification of the therapeutic benefit 
undoubtedly remain to be defined by carefully designed 
clinical trials.
The cellular and molecular heterogeneity in the primary 
tumor presumably facilitates the development of therapy-
resistant cell clones, which are not necessarily the origin 
of metastatic cells. Therefore, metastatic tumor cells by 
themselves may remain therapy-sensitive. We hypothesize 
that primary PCa including tumor cells and stroma cells 
or the specific prostate microenvironment influences the 
therapy response and plays an active role in resistance to 
systemic treatments and progression at metastatic sites. 
This concept is supported by recently published in-vitro 
data. The data demonstrate that the crosstalk between 
androgen-sensitive PCa cells and androgen-insensitive 
PCa cells might stimulate the progression of PCa [35]. 
Furthermore, therapy resistance can be induced in sensi-
tive tumor cells by exosomes secreted by the tumor or 
stroma cells from resistant tumors, as demonstrated for 
several tumor types and therapy modalities [36].
As soon as the hypothesis of a “hormone-sensitizing” 
character of a prostatectomy can be proven by more 
robust data, the underlying molecular mechanisms will 
gain increased interest. Targeting these mechanisms could 
dramatically change PCa treatment concepts and finally 
fulfill Huggins’ vision: the curability of PCa at any stage 
of disease.
Conclusion
Multiple data suggest a survival benefit for patients suffer-
ing from metastasized PCa by the treatment of the primary 
tumor-bearing prostate. The mode of action, however, 
has not been clarified to date. We present a patient series 
characterized by long-lasting or even unlimited sensitivity 
to various forms of hormonal treatment with a common 
denominator of a prior prostatectomy. This suggests that 
the removal or treatment of the primary tumor-bearing 
prostate modulates, delays, and/or even prevents resist-
ance to ADT and can therefore lead to the chronification 
of metastatic PCa.
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